Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: When three water molecules and the keto-enol tautomerism make the difference

Journal of Medicinal Chemistry

Volumn 52, Issue 2, 2009, Pages 322-328

  Temperini, Claudia ^a   Cecchi, Alessandro ^a   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CHLORTALIDONE; INDAPAMIDE; ISOENZYME; WATER;

ARTICLE; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; STEREOISOMERISM;

CARBONIC ANHYDRASE INHIBITORS; CATALYTIC DOMAIN; CHLORTHALIDONE; CRYSTALLOGRAPHY, X-RAY; INDAPAMIDE; ISOENZYMES; MODELS, MOLECULAR; STEREOISOMERISM; WATER;

EID: 60549085611     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801386n     Document Type: Article

References (48)

1. (a). Padilla, M. C.; Armas-Hernández, M. J.; Hernández, R. H.; Israili, Z. H.; Valasco, M. Update of diuretics in the treatment of hypertension. Am. J. Ther. 2007, 14, 154-160.
2. (b). Smith, R. E.; Ashiya, M. Antihypertensive therapies. Nat. Rev. Drug Discovery 2007, 6, 597-598.
3. (a). ADVANCE Collaborative Group. MacMahon, S.; Chalmers, J.; Neal, B.; Woodward, M.; Billot, L.; Harrap, S.; Poulter, N.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D. E.; Hamet, P.; Heller, S.; Liu, L. S.; Mancia, G.; Mogensen, C. E.; Pan, C. Y.; Rodgers, A.; Williams, B.; Patel, A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370, 829-840.
4. (b). Piecha, G.; Adamczak, M.; Chudek, J.; Wiecek, A. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Pressure Res. 2007, 30, 187-94.
5. (c). Zannad, F. Benefits of first line combination of perindopril and indapamide in clinical practice for patients with hypertension and diabetes. Am. J. Hepertens. 2007, 20,9S-14S.
6. (d). Sica, D. A. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 2006, 47, 321-322.
7. (a). Nishioku, T.; Takata, F.; Yamauchi, A.; Sumi, N.; Yamamoto, I.; Fujino, A.; Naito, M.; Tsuruo, T.; Shuto, H.; Kataoka, Y. Protective action of indapamide, a thiazide-like diuretic, on ischemia-induced injury and barrier dysfunction in mouse brain microvascular endothelial cells. J. Pharmacol. Sci. 2007, 103, 323-327.
8. (b). Smith, D. H. Fixed dose combination antihypertensives and reduction in target organ damage: are they all the same. Am. J. Cardiovasc. Drugs 2007, 7, 413-422.
9. (c). Pickkers, P.; Garcha, R. S.; Schachter, M.; Smits, P.; Hughes, A. D. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension 1999, 33, 1043-1048.
10. (a). Dell'Omo, G.; Penno, G.; Del Prato, S.; Pedrinelli, R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J. Cardiovasc. Pharmacol. Ther. 2005, 10, 265-72.
11. (b). Struijker-Boudier, H. A. From macrocirculation to microcirculation: benefits of preterax. Am. J. Hepertens. 2007, 20, 15S-18S.
12. Patel, A. B.; Kostis, J. B.; Wilson, A. C.; Shea, M. L.; Pressel, S. L.; Davis, B. R. Long-term fatal outcomes in subjects with stroke or transient ischemic attack. Fourteen-year follow-up of the Systolic Hypertension in the Elderly program. Stroke, in press.
13. (a). Black, H. R.; Davis, B.; Barzilay, J.; Nwachuku, C.; Baimbridge, C.; Marginean, H.; Wright, J. T.; Basile, J.; Wong, N. D.; Whelton, P.; Dart, R. A.; Thadani, U. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008, 31, 353-360.
14. (b). Herraez-Fernandez, R.; Campins-Falco, P. Chromatographic separation of chlorthalidone enantiomers using /3-cyclodextrins as chiral additives. J. Chromatogr. B 2000, 740, 169-177.
15. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drue Discovery 2008, 7, 168-181.
16. (a). Temperini, C.; Cecchi, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with twelve mammalian isozymes and X-ray crystallographic studies for the indapamide- isozyme II adduct.Bioorg. Med. Chem. Lett. 2008, 18, 2567-2573.
17. (b). Temperini, C.; Cecchi, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited-old leads for new applications. Org. Biomol. Chem. 2008, 6, 2499-2506.
18. Supuran, C. T. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr. Pharm. Des. 2008, 14, 641-648.
19. (a). Supuran, C. T.; Scozzafava, A.; Conway, J. Carbonic Anhydrase. Its Inhibitors and Activators; CRC Press: Boca Raton, FL, 2004; pp 1-363.
20. (b). Köhler, K.; Hillebrecht, A.; Schulze Wischeler, J.; Innocenti, A.; Heine, A.; Supuran, C. T.; Klebe, G. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew. Chem., Int. Ed. 2007, 46, 7697-7699.
21. (a). Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
22. (b). Supuran, C. T.; Scozzafava, A.; Casini, A. Development of Sulfonamide Carbonic Anhydrase Inhibitors. In Carbonic Anhydrase. Its Inhibitors and Activators; Supuran, C. T., Scozzafava, A., Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 67-147.
23. (c). Thiry, A.; Dogné, J. M.; Masereel, B.; Supuran, C. T. Targeting tumor- associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 2006, 27, 566-573.
24. (a). Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-89.
25. (b). Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. iPat. 2004, 14, 667-702.
26. (c). Winum, J. Y.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. Mini-Rev. Med. Chem. 2006, 6, 921-936.
27. (d). Supuran, C. T. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Pat. 2003, 13, 1545-1550.
28. (a). Krishnamurthy, V. M.; Kaufman, G. K.; Urbach, A. R.; Gitlin, I.; Gudiksen, K. L.; Weibel, D. B.; Whitesides, G. M. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem. Rev. 2008, 108, 946-1051.
29. (b). Stiti, M.; Cecchi, A.; Rami, M.; Abdaoui, M.; Barragan-Montero, V.; Scozzafava, A.; Guari, Y.; Winum, J. Y.; Supuran, C. T. Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. J. Am. Chem. Soc. 2008, 130, 16130-16131.
30. Thiry, A.; Dogne, J. M.; Supuran, C. T.; Masereel, B. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr. Pharm. Des. 2008, 14, 661-671.
31. (a). Supuran, C. T.; Di Fiore, A.; De Simone, G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin. Emerging Drugs 2008, 13, 383-92.
32. (b). De Simone, G.; Di Fiore, A.; Supuran, C. T. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr. Pharm. Des. 2008, 14, 655-660.
33. (a). Dubois, L.; Douma, K.; Supuran, C. T.; Chiu, R. K.; van Zandvoort, M. A. M. J.; Pastorekova, S.; Scozzafava, A.; Wouters, B. G.; Lambin, P. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol. 2007, 83, 367-373.
34. (b). D'Ambrosio, K.; Vitale, R. M.; Dogne, J. M.; Masereel, B.; Innocenti, A.; Scozzafava, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J. Med. Chem. 2008, 51, 3230-3237.
35. (c). Thiry, A.; Supuran, C. T.; Masereel, B.; Dogne, J. M. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J. Med. Chem. 2008, 51, 3051-3056.
36. Guzel, O.; Temperini, C.; Innocenti, A.; Scozzafava, A.; Salman, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 2008, 18, 152-158.
37. Nishimori, I.; Minakuchi, T.; Onishi, S.; Vullo, D.; Cecchi, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg. Med. Chem. 2007, 15, 7229-7236.
38. (a). Vullo, D.; Franchi, M.; Gallori, E.; Antel, J.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. J. Med. Chem. 2004, 47, 1272-1279.
39. (b). Nishimori, I.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J. Med. Chem. 2005, 48, 7860-7866.
40. Vullo, D.; Voipio, J.; Innocenti, A.; Rivera, C.; Ranki, H.; Scozzafava, A.; Kaila, K.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 971-976.
41. (a). Nishimori, I.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 3828-3833.
42. (b). Ozensoy, O.; Nishimori, I.; Vullo, D.; Puccetti, L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the human transmembrane isozyme XIV with a library of aromatic/heterocyclic sulfonamides. Bioorg. Med. Chem. 2005, 13, 6089-6093.
43. Vullo, D.; Innocenti, A.; Nishimori, I.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides. A new target for the design of antitumor and antiglaucoma drugs. Bioorg. Med. Chem. Lett. 2005, 15, 963-969.
44. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and Cd. J. Biol. Chem. 1971, 246, 2561-2573.
45. Leslie, A. G. W. MOSFLM User's Guide; MRC-LMB: Cambridge, U.K., 1994.
46. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 1994, 50, 760-763.
47. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunsteleve, R. W.; Fiang, J.; Kuszewsky, J.; Niles, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simmonson, T.; Warren, G. L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 1998, 54, 905-921.
48. Jones, T. A.; Zhou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 1991, 47, 110-119. JM801386N